Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 11c

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.27), $0.11 worse than the analyst estimate of ($0.16).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Morgan Stanley lifts server market TAM to $809B, boosts targets on compute stocks
• Carnival shares drop despite earnings beat on weak guidance